Pemitinib Tablets β Pemigatinib 13.5 mg (14 Tabs) Everest
22825β΄
25458β΄
-10%
Pemitinib 13.5 mg is a targeted kinase inhibitor and a generic equivalent to Pemazyre. It is designed to treat specific types of cancer by blocking fibroblast growth factor receptors (FGFR), stopping cancer cells from growing and dividing.
Manufacturer: Everest Pharmaceuticals (Bangladesh). This medication represents a precision medicine approach for patients with specific genetic biomarkers.
Key Features:
- β Mechanism of Action: Potent inhibitor of FGFR1, FGFR2, and FGFR3 tyrosine kinases.
- β Targeted Efficacy: Specifically effective for tumors harboring FGFR2 fusions or rearrangements.
- β Second-Line Therapy: Provides a treatment option for bile duct cancer patients who have progressed after chemotherapy.
Prescribed by oncologists for adults with:
- πΉ Cholangiocarcinoma (Bile Duct Cancer): Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a confirmed FGFR2 fusion or other rearrangement.
- πΉ Myeloid/Lymphoid Neoplasms: With FGFR1 rearrangement (relapsed or refractory).
Sales Unit: Bottle containing 14 film-coated tablets (13.5 mg strength).
β οΈ APPLICATION INSTRUCTIONS:
- Standard Dosage: Take one tablet (13.5 mg) orally once daily at approximately the same time every day.
- Cycle Schedule: Take for 14 consecutive days followed by a 7-day break (21-day cycle). Continue as long as beneficial.
- Administration: Swallow whole with or without food. Do not crush, chew, or split the tablet.
- β Missed Dose: If missed by more than 4 hours, skip it. Resume regular schedule the next day. Do not take 2 tablets to make up for the missed dose.
- β Pregnancy & Breastfeeding: Can cause fetal harm. Effective contraception is required during treatment and for 1 week after the last dose.
- Pediatric patients (safety not established).
- Hypersensitivity to Pemitinib or any excipients.
- Co-administration with strong CYP3A inducers (e.g., St. John's wort) should be avoided.
- β Pregnancy & Breastfeeding: Can cause fetal harm. Effective contraception is required during treatment and for 1 week after the last dose.
- Pediatric patients (safety not established).
- Hypersensitivity to Pemitinib or any excipients.
- Co-administration with strong CYP3A inducers (e.g., St. John's wort) should be avoided.
100% original product
Delivery across Ukraine
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!